Document Detail

Clinical pharmacokinetics and interaction of centchroman--a mini review.
MedLine Citation:
PMID:  20227542     Owner:  NLM     Status:  MEDLINE    
This article provides a brief review of the information available regarding the published pharmacokinetics data for the nonsteroidal, once-a-week oral contraceptive, centchroman (INN: ormeloxifene). This agent is a unique need-oriented contraceptive agent which is included in the National Family Welfare Programme of India. Since 1991, centchroman has been used as a need-oriented contraceptive and is being given for treating dysfunctional bleeding of the uterus. Information regarding absorption, tissue distribution, elimination and kinetic interactions is discussed.
Jawahar Lal
Publication Detail:
Type:  Journal Article; Review     Date:  2010-01-04
Journal Detail:
Title:  Contraception     Volume:  81     ISSN:  1879-0518     ISO Abbreviation:  Contraception     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-03-15     Completed Date:  2010-06-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0234361     Medline TA:  Contraception     Country:  United States    
Other Details:
Languages:  eng     Pagination:  275-80     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Elsevier Inc. All rights reserved.
Pharmacokinetics and Metabolism Division, Central Drug Research Institute, CSIR, Lucknow, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Centchroman / pharmacokinetics*
Contraceptives, Oral / pharmacokinetics*
Contraceptives, Postcoital, Synthetic / pharmacokinetics*
Drug Interactions
Uterine Hemorrhage / drug therapy
Reg. No./Substance:
0/Contraceptives, Oral; 0/Contraceptives, Postcoital, Synthetic; 31477-60-8/Centchroman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Flexible mifepristone and misoprostol administration interval for first-trimester medical terminatio...
Next Document:  Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone aceta...